The Analyst Landscape: 6 Takes On Silence Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts' ratings for Silence Therapeutics (NASDAQ:SLN) over the last quarter vary from bullish to bearish. The average 12-month price target is $64.5, with a high of $75.00 and a low of $42.00. Key analysts have maintained their ratings and price targets, reflecting their perspectives on the company's market position and financial health.
June 20, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts' ratings for Silence Therapeutics (NASDAQ:SLN) show a mix of bullish to bearish sentiments. The average 12-month price target is $64.5, with a high of $75.00 and a low of $42.00. Key analysts have maintained their ratings and price targets, reflecting their perspectives on the company's market position and financial health.
The mixed analyst ratings and stable price targets suggest a neutral short-term impact on Silence Therapeutics' stock price. The company's financial health indicators and maintained ratings by key analysts provide a balanced view, neither strongly positive nor negative.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100